Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Ossur Hf : Transactions in relation to share buyback program


Posted on: 23 Oct 17

Announcement from Össur hf. No. 11/2018
Reykjavík, 19 February 2018


On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. 

The purpose of the share buyback program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Dividend Policy. The program will end no later than 31 July 2018. The Company may purchase up to 5,000,000 shares under the program, corresponding to 1.1% of the current share capital. The total consideration for shares purchased under the program shall not exceed USD 10 million.

The following transactions were made under the program in week 27, the period 12 February 2018 - 16 February 2018:

Date No. of shares Avg. purchase price DKK Transaction Value DKK
12 February 2018 6,651 29.44 195,825
13 February 2018 15,460 29.86 461,620
14 February 2018 8,047 29.99 241,337
15 February 2018 4,487 29.72 133,354
16 February 2018 10,000 29.51 295,144
Total   44,645 29.73 1,327,280

Össur has acquired 1,961,868 shares under the program at the average price of DKK 29.38. Following the above transactions Össur's holding of own shares is 10,078,473 corresponding to 2.31% of the Company's total share capital.

The share buyback program is carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission delegated regulation No. 2016/1052.                                                                                                                                                                                                                 

Contact persons:

Jón Sigurðsson, President & CEO                                         Tel: +354 515 1300

Sveinn Sölvason, CFO                                                          Tel: +354 515 1300

Össur press releases by e-mail: If you wish to receive Össur press releases by e-mail please register at the following web-site: http://www.ossur.com/investormailings

About Össur Össur (NASDAQ: OSSR) is a global leader in non-invasive orthopedics that help people live a life without limitations. Its business is focused on improving people's mobility through the delivery of innovative technologies within the fields of braces, supports and prosthetic limbs. A recognized "Technology Pioneer", Össur invests significantly in research and product development; its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Össur's educational programs and business solutions.  Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. www.ossur.com

Forward-Looking Statement This press release includes "forward-looking statements" which involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Össur hf. undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/84b33e23-2e1e-4d32-86e2-1f36bfdb1400

GlobeNewswire
globenewswire.com

Last updated on: 20/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.